Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | BAX | Q07812 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410479 | 1.00 | CA4 (0.42) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL4151573 | 1.00 | CA4 (0.42) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL7363159 | 0.81 | LTA4H (0.45) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL1394693 | 0.80 | TDP1 (0.43) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL17986235 | 0.79 | LTA4H (0.38) | CA4LTA4HTSHRL3MBTL1MAOA | |
| SCHEMBL17986234 | 0.79 | LTA4H (0.38) | CA4LTA4HTSHRL3MBTL1MAOA | |
| SCHEMBL10765298 | 0.79 | LTA4H (0.43) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL9653942 | 0.75 | LTA4H (0.39) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL6193811 | 0.75 | LTA4H (0.39) | CA4LTA4HTSHRL3MBTL1TDP1 | |
| SCHEMBL6193817 | 0.75 | LTA4H (0.39) | CA4LTA4HTSHRL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | claimed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | claimed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | claimed |
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023286855-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | クミアイ化学工業株式会社 | 2023-01-19 | — | — | WO | disclosed |
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | CA4 3545/4885LTA4H 399/4885TSHR 244/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | CA4 3545/4885LTA4H 399/4885TSHR 244/4885 |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | CA4 1953/4885LTA4H 1589/4885TSHR 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.